BioAge Labs, Inc (NASDAQ:BIOA) — Market Cap & Net Worth
Market Cap & Net Worth: BioAge Labs, Inc (BIOA)
BioAge Labs, Inc (NASDAQ:BIOA) has a market capitalization of $355.70 Million ($355.70 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14096 globally and #3372 in its home market, demonstrating a -17.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioAge Labs, Inc's stock price $7.75 by its total outstanding shares 45896909 (45.90 Million). Also see BIOA total asset value for a full breakdown of the balance sheet.
BioAge Labs, Inc Market Cap History: 2024 to 2026
BioAge Labs, Inc's market capitalization history from 2024 to 2026. Data shows change from $265.74 Million to $355.70 Million (-35.33% CAGR). Also see BIOA cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
BioAge Labs, Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.01% | #383 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1375 of 3165 |
Weight: BioAge Labs, Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioAge Labs, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioAge Labs, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BioAge Labs, Inc (BIOA) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
67.51x
BioAge Labs, Inc's market cap is 67.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $607.22 Million | $8.99 Million | -$80.61 Million | 67.51x | N/A |
Competitor Companies of BIOA by Market Capitalization
Companies near BioAge Labs, Inc in the global market cap rankings as of September 17, 2026. Review BioAge Labs, Inc tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to BioAge Labs, Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
BioAge Labs, Inc Historical Marketcap From 2024 to 2026
Between 2024 and today, BioAge Labs, Inc's market cap moved from $265.74 Million to $ 355.70 Million, with a yearly change of -35.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $355.70 Million | -41.42% |
| 2025 | $607.22 Million | +128.50% |
| 2024 | $265.74 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of BioAge Labs, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $355.70 Million USD |
| MoneyControl | $355.70 Million USD |
| MarketWatch | $355.70 Million USD |
| marketcap.company | $355.70 Million USD |
| Reuters | $355.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more